113 related articles for article (PubMed ID: 37131684)
1. ERK Hyperactivation Serves as a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous Melanoma.
Rebecca V; Jagirdar K; Portuallo M; Wei M; Wilhide M; Bravo J; Robertson B; Alicea G; Aguh C; Xiao M; Godok T; Fingerman D; Brown G; Herlyn M; Guo B; Toska E; Zabransky D; Wubbenhorst B; Nathanson K; Kwatra S; Goyal Y; Ji H; Liu Q
Res Sq; 2023 Apr; ():. PubMed ID: 37131684
[TBL] [Abstract][Full Text] [Related]
2. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma.
Jagirdar K; Portuallo ME; Wei M; Wilhide M; Bravo Narula JA; Robertson BM; Alicea GM; Aguh C; Xiao M; Godok T; Fingerman D; Brown GS; Herlyn M; Elad VM; Guo X; Toska E; Zabransky DJ; Wubbenhorst B; Nathanson KL; Kwatra S; Goyal Y; Ji H; Liu Q; Rebecca VW
Oncogene; 2024 Feb; 43(6):395-405. PubMed ID: 38066089
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
4. MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.
Vilgelm AE; Saleh N; Shattuck-Brandt R; Riemenschneider K; Slesur L; Chen SC; Johnson CA; Yang J; Blevins A; Yan C; Johnson DB; Al-Rohil RN; Halilovic E; Kauffmann RM; Kelley M; Ayers GD; Richmond A
Sci Transl Med; 2019 Aug; 11(505):. PubMed ID: 31413145
[TBL] [Abstract][Full Text] [Related]
5. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
6. TERT amplification but not activation of canonical Wnt/β-catenin pathway is involved in acral lentiginous melanoma progression to metastasis.
Ramani NS; Aung PP; Gu J; Sfamenos S; Sdringola-Maranga C; Nagarajan P; Tetzlaff MT; Curry JL; Ivan D; Diab A; Prieto VG; Hwu WJ; Torres-Cabala CA
Mod Pathol; 2020 Oct; 33(10):2067-2074. PubMed ID: 32404956
[TBL] [Abstract][Full Text] [Related]
7. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
De Angelis C; Fu X; Cataldo ML; Nardone A; Pereira R; Veeraraghavan J; Nanda S; Qin L; Sethunath V; Wang T; Hilsenbeck SG; Benelli M; Migliaccio I; Guarducci C; Malorni L; Litchfield LM; Liu J; Donaldson J; Selenica P; Brown DN; Weigelt B; Reis-Filho JS; Park BH; Hurvitz SA; Slamon DJ; Rimawi MF; Jansen VM; Jeselsohn R; Osborne CK; Schiff R
Clin Cancer Res; 2021 Sep; 27(17):4870-4882. PubMed ID: 33536276
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
[TBL] [Abstract][Full Text] [Related]
9. The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer.
Gomes I; Abreu C; Costa L; Casimiro S
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835528
[TBL] [Abstract][Full Text] [Related]
10. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
Nassar KW; Hintzsche JD; Bagby SM; Espinoza V; Langouët-Astrié C; Amato CM; Chimed TS; Fujita M; Robinson W; Tan AC; Schweppe RE
Mol Cancer Ther; 2021 Oct; 20(10):2049-2060. PubMed ID: 34376578
[TBL] [Abstract][Full Text] [Related]
11. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
12.
Teh JLF; Cheng PF; Purwin TJ; Nikbakht N; Patel P; Chervoneva I; Ertel A; Fortina PM; Kleiber I; HooKim K; Davies MA; Kwong LN; Levesque MP; Dummer R; Aplin AE
Cancer Discov; 2018 May; 8(5):568-581. PubMed ID: 29496664
[TBL] [Abstract][Full Text] [Related]
13. Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer.
Gomes I; Gallego-Paez LM; Jiménez M; Santamaria PG; Mansinho A; Sousa R; Abreu C; Suárez EG; Costa L; Casimiro S
Cell Rep Med; 2023 Aug; 4(8):101120. PubMed ID: 37451269
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and Management of Acral Lentiginous Melanoma.
Nakamura Y; Fujisawa Y
Curr Treat Options Oncol; 2018 Jun; 19(8):42. PubMed ID: 29951919
[TBL] [Abstract][Full Text] [Related]
15. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
16. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
[TBL] [Abstract][Full Text] [Related]
17. Expression of p16 protein in acral lentiginous melanoma.
Hsieh R; Firmiano A; Sotto MN
Int J Dermatol; 2009 Dec; 48(12):1303-7. PubMed ID: 20415670
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
O'Sullivan CC; Clarke R; Goetz MP; Robertson J
JAMA Oncol; 2023 Sep; 9(9):1273-1282. PubMed ID: 37382948
[TBL] [Abstract][Full Text] [Related]
19. Progression from Acral Lentiginous Melanoma in situ to Invasive Acral Lentiginous Melanoma.
Bae JM; Kim HO; Park YM
Ann Dermatol; 2009 May; 21(2):185-8. PubMed ID: 20523783
[TBL] [Abstract][Full Text] [Related]
20. Acral lentiginous melanoma: Clinicopathologic and survival differences according to tumour location.
Howard M; Xie C; Wee E; Wolfe R; McLean C; Kelly JW; Pan Y
Australas J Dermatol; 2020 Nov; 61(4):312-317. PubMed ID: 32363586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
